Indications for, and the significance of, the tuberculin test in the Netherlands;Indicaties voor en betekenis van de tuberculinetest in Nederland

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 12, 2003, Pages 539-543

  Verbon, A ^a,b,c   Cobelens, F G J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

AGING; BCG VACCINATION; CELLULAR IMMUNITY; CROSS REACTION; DIAGNOSTIC TEST; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; NONHUMAN; REVIEW; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

BCG VACCINE; HUMANS; NETHERLANDS; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0037460867     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Koch R. Uber bacteriologische Forschung. Dtsch Med Wochenschr 1890;16:756.
2. Von Pirquet C. Frequency of tuberculosis in childhood. JAMA 1907;52:675-8.
3. Mantoux MC. La voie intradermique en tuberculinothérapie. Presse Med 1912;20:146-8.
4. Seibert FB, Glenn JT. Tuberculin purified protein derivative: preparation and analysis of a large quantity for standard. Am Rev Tuberc 1941;44:49.
5. Guld J, Bentzon MW, Bleiker MA, Griep WA, Magnuson M, Waaler H. Standardization of a new batch of purified tuberculin (PPD) intended for international use. Bull WHO 1958;19:845-951.
6. The WHO standard tuberculin test. Genève: World Health Organization; 1963.
7. Poortman GH, Breejen A den, Valk PDLPM van der, Palen J van der. Parate kennis over de uitvoering van de Mantoux-test onvoldoende. Ned Tijdschr Geneeskd 1999;143:851-5.
8. Menzies D. Tuberculin skin testing. In: Reichman LB, Hershfield ES, editors. Tuberculosis. A comprehensive international approach. 2nd rev ed. New York: Marcel Dekker; 2000. p. 279-322.
9. Steiner P, Rao M, Victoria MS, Jabbar H, Steiner M. Persistently negative tuberculin reactions: their presence among children with culture positive for Mycobacterium tuberculosis (tuberculin-negative tuberculosis). Am J Dis Child 1980;134:747-50.
10. American Thoracic Society. The tuberculin test. Am Rev Respir Dis 1981;124:356-63.
11. Veen J. Aspects of temporary specific anergy to tuberculin in Vietnamese refugees [proefschrift]. Groningen: Rijksuniversiteit Groningen; 1992. p. 1-119.
12. Lundin AP, Adler AJ, Berlyne GM, Friedman EA. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979;67:597-602.
13. Schatz M, Patterson R, Kloner R, Falk J. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med 1976;84:261-5.
14. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992;268:504-9.
15. Kritski AL, Werneck-Barroso E, Vieira MA, Carvalho AC, Carvalho CE, Bravo-de Souza R, et al. HIV infection in 567 active pulmonary tuberculosis patients in Brazil. J Acquir Immune Defic Syndr 1993;6:1008-12.
16. Blusse van Oud-Alblas HJ, Vliet ME van, Kimpen JL, de Villiers GS, Schaaf HS, Donald PR. Human immunodeficiency virus infection in children hospitalised with tuberculosis. Ann Trop Paediatr 2002;22:115-23.
17. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. Clin Infect Dis 1994;19:26-32.
18. Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA 2000;283:2003-7.
19. Woodruff CE, Chapman PT. Tuberculin sensitivity in elderly patients. Am Rev Respir Dis 1971;104:261-3.
20. Brande P van den, Demedts M. Four-stage tuberculin testing in elderly subjects induces age-dependent progressive boosting. Chest 1992;101:447-50.
21. Palmer CE. Tuberculin sensitivity and contact with tuberculosis: further evidence of non-specific sensitivity. Am Rev Tuberc 1953;68:678-94.
22. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969;99 Suppl:1-132.
23. Guld J. Interpretation of tuberculin reactions in populations with a high proportion of BCG-vaccinated. Bull WHO 1957;17:225.
24. Menzies D. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us? Clin Infect Dis 2000;31 Suppl 3:S71-4.
25. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21.
26. Sutherland I. The ten-year incidence of clinical tuberculosis following 'conversion' in 2,550 individuals aged 14 to 19 years. TSRU Progress report. Den Haag: KNCV; 1968.
27. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000;49(RR-6):1-51.
28. Styblo K, Broekmans J, Borgdorff M. Expected decrease in the tuberculosis incidence during the elimination phase: how to determine its trend? TSRU report. Den Haag: KNCV; 1997.
29. Bass jr JA, Serio RA. The use of repeat skin tests to eliminate the booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1981;123(4 Pt 1):394-6.
30. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702.